Bulk Pharmaceutical API Sources for RENVELA

Bulk Pharmaceutical API Sources for RENVELA

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemMol		49403929
Key Organics/BIONET		HS-0081
AN PharmaTech		AN-9605

RENVELA Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) manufacturers and suppliers for Renvela (sevelamer carbonate), a phosphate binder used to treat hyperphosphatemia in patients with chronic kidney disease. The analysis focuses on key manufacturing regions, notable API producers, regulatory considerations, and market dynamics impacting sourcing strategies.

What is Renvela and What is Its Therapeutic Application?

Renvela is the brand name for sevelamer carbonate, a non-calcium, aluminum-free phosphate binder. It is prescribed to patients with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis to control serum phosphorus levels. By binding to phosphate in the gastrointestinal tract, it prevents its absorption, thereby reducing hyperphosphatemia [1]. Sevelamer carbonate functions by cross-linking with dietary phosphate, forming an insoluble complex that is then eliminated from the body in the feces.

Who are the Primary Manufacturers of Sevelamer Carbonate API?

The production of sevelamer carbonate API is concentrated in regions with established pharmaceutical manufacturing infrastructure and regulatory compliance capabilities. Key regions include China, India, and to a lesser extent, Europe.

Several companies globally are known to manufacture or supply sevelamer carbonate API. Identifying all entities is challenging due to the proprietary nature of supply chains and potential for contract manufacturing. However, based on regulatory filings, patent literature, and industry reports, prominent players include:

• Generic API Manufacturers: These companies specialize in producing APIs for off-patent drugs. They often supply to finished dosage form (FDF) manufacturers globally.
• Contract Manufacturing Organizations (CMOs): Some CMOs are involved in the synthesis of sevelamer carbonate for various clients, adhering to specific quality and regulatory standards.

A representative, non-exhaustive list of entities that have been associated with sevelamer carbonate API production or supply includes:

• JW Pharmaceutical (South Korea): A notable player with a history in API manufacturing.
• Hetero Drugs Ltd. (India): A significant Indian pharmaceutical company with broad API capabilities.
• Dr. Reddy's Laboratories (India): Another major Indian API producer with a diverse portfolio.
• Sun Pharmaceutical Industries Ltd. (India): A leading global pharmaceutical company with substantial API manufacturing operations.
• VHB Life Sciences Ltd. (India): An emerging player in the API space.
• Lupin Ltd. (India): A global pharmaceutical company with strong R&D and manufacturing in APIs.
• Various Chinese API Manufacturers: China hosts a large number of API manufacturers, many of whom are qualified suppliers for international markets. Specific company names often appear in drug master files (DMFs) submitted to regulatory agencies.

It is critical for sourcing professionals to conduct thorough due diligence on any potential supplier, including site audits, quality agreements, and verification of regulatory compliance.

What are the Key Regulatory Considerations for Sevelamer Carbonate API Sourcing?

Sourcing sevelamer carbonate API requires strict adherence to global regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements are paramount:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying API for products marketed in the U.S. must comply with FDA regulations, including Current Good Manufacturing Practices (cGMP). API suppliers must file Drug Master Files (DMFs) with the FDA, detailing manufacturing processes, quality controls, and stability data. The FDA conducts inspections of manufacturing facilities to ensure compliance.
• European Medicines Agency (EMA): For the European market, API manufacturers must comply with EMA guidelines and EU GMP standards. Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP) are often required, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
• Other National Regulatory Authorities: Agencies in countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) have their own specific requirements for API registration and import.
• Pharmacopoeial Standards: Sevelamer carbonate API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, assay, and impurity limits.

Table 1: Key Regulatory Requirements for API Sourcing

Regulatory Body	Primary Requirement	Documentation
U.S. FDA	cGMP Compliance, Facility Inspection	Drug Master File (DMF)
EMA	EU GMP Standards, Site Audits	Certificate of Suitability (CEP), ASMF/EDMF
EDQM	Compliance with Ph. Eur. monographs	Certificate of Suitability (CEP)
PMDA (Japan)	GMP compliance, Foreign Manufacturer Accreditation	DMF, Manufacturing Site Information
Health Canada	GMP compliance, Site Inspections	API Site Master File (APISM), DMF

Sourcing decisions must prioritize suppliers with a demonstrated history of regulatory compliance and a robust quality management system.

What is the Typical Manufacturing Process for Sevelamer Carbonate API?

The synthesis of sevelamer carbonate involves a multi-step chemical process. While specific proprietary details vary between manufacturers, the general pathway typically includes polymerization of allylamine followed by cross-linking and carbonate formation.

1. Polymerization: Allylamine is polymerized to form polyallylamine.
2. Cross-linking: The polyallylamine is cross-linked, commonly using epichlorohydrin, to form poly(allylamine hydrochloride).
3. Ion Exchange and Carbonate Formation: The poly(allylamine hydrochloride) is then converted to the carbonate salt. This involves treating the polymer with a source of carbonate ions, such as sodium carbonate or carbon dioxide in the presence of a base, to form sevelamer carbonate.

Key Process Considerations:

• Impurity Profile: Control of residual monomers, cross-linking agents, and related substances is critical. Manufacturers must demonstrate consistent control over the impurity profile to meet pharmacopoeial limits.
• Physical Properties: Particle size distribution, surface area, and swelling properties of the sevelamer carbonate API can influence the dissolution rate and binding capacity of the finished drug product. These parameters are tightly controlled during manufacturing and downstream processing.
• Stability: The API must exhibit adequate stability under specified storage conditions. Stability studies are a core component of regulatory submissions.

What are the Market Dynamics and Sourcing Challenges?

The global market for sevelamer carbonate API is influenced by several factors, including patent expiries, generic competition, and evolving regulatory landscapes.

• Generic Competition: With the patent expiry of the originator product (Renagel, and later Renvela), there has been increased competition from generic manufacturers. This drives demand for cost-effective API sourcing.
• Supply Chain Volatility: Geopolitical events, trade policies, and global health crises can impact the stability and cost of API supply. Diversification of sourcing regions is a key risk mitigation strategy.
• Quality and Compliance Risks: Ensuring consistent API quality and adherence to cGMP across multiple suppliers and regions remains a primary challenge. Thorough supplier qualification and ongoing monitoring are essential.
• Cost Pressures: Generic drug manufacturers face significant pressure to reduce the cost of goods sold, which translates to stringent price negotiations with API suppliers.
• Environmental, Social, and Governance (ESG) Factors: Increasingly, pharmaceutical companies are scrutinizing their suppliers' ESG performance, including environmental impact and labor practices.

Table 2: Key Market Dynamics for Sevelamer Carbonate API

Factor	Impact on Sourcing
Generic Competition	Increased demand for cost-competitive API; Price sensitivity
Regulatory Scrutiny	Higher compliance costs; Need for validated suppliers with strong regulatory track record
Supply Chain Security	Risk of disruption; Importance of dual sourcing and geographical diversification
Quality Assurance	Non-negotiable requirement; necessitates robust auditing and quality agreements
Raw Material Costs	Fluctuations can impact API pricing; supplier should have secure raw material procurement

What are the Strategic Sourcing Approaches?

Effective sourcing of sevelamer carbonate API requires a strategic approach that balances cost, quality, and supply reliability.

1. Supplier Qualification and Auditing:

   • Conduct rigorous due diligence on potential API manufacturers.
   • Perform on-site cGMP audits to assess manufacturing capabilities, quality systems, and regulatory compliance.
   • Review DMFs and regulatory inspection reports.

2. Dual or Multi-Sourcing:

   • Establish relationships with at least two qualified API suppliers to mitigate supply chain disruptions.
   • Diversify suppliers geographically to reduce dependence on a single region.

3. Quality Agreements:

   • Develop comprehensive Quality Agreements (QAs) with each supplier, clearly defining roles, responsibilities, change control procedures, and dispute resolution mechanisms.

4. Long-Term Contracts:

   • Negotiate long-term supply contracts with key suppliers to secure pricing and ensure supply continuity. These contracts should include clauses addressing potential market changes and force majeure events.

5. Regulatory Intelligence:

   • Stay informed about evolving regulatory requirements in target markets and monitor regulatory actions against API manufacturers.

Key Takeaways

• Sevelamer carbonate API manufacturing is concentrated in established pharmaceutical hubs, notably China and India, with significant players like JW Pharmaceutical, Hetero Drugs, and Dr. Reddy's Laboratories being key entities.
• Stringent regulatory compliance with FDA, EMA, and other national authorities, including cGMP adherence and DMF submissions, is non-negotiable.
• The synthesis of sevelamer carbonate is a complex multi-step process requiring precise control over impurity profiles and physical properties.
• The market is characterized by robust generic competition, driving cost pressures, and necessitating robust supply chain risk management strategies.
• Strategic sourcing involves rigorous supplier qualification, dual-sourcing, comprehensive quality agreements, and continuous regulatory intelligence.

Frequently Asked Questions

1. What are the primary pharmacopoeial standards that sevelamer carbonate API must meet? Sevelamer carbonate API must meet the specifications outlined in the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), including requirements for identity, purity, assay, and impurity limits.

2. Can a single manufacturing site in China supply sevelamer carbonate API to both the U.S. and European markets? Yes, a single manufacturing site can supply to both markets if it complies with the respective regulatory requirements (FDA's cGMP and EMA's EU GMP) and has the necessary filings (e.g., DMF for the U.S., ASMF/EDMF for Europe) accepted by the regulatory authorities.

3. What are the main impurities to monitor in sevelamer carbonate API? Key impurities to monitor include residual monomers (e.g., allylamine), residual cross-linking agents (e.g., epichlorohydrin), related polymers, and degradation products. Control of these impurities is critical for product safety and efficacy.

4. How can a generic drug manufacturer ensure the long-term availability of sevelamer carbonate API? Long-term availability is best ensured through establishing relationships with multiple qualified suppliers, negotiating long-term supply agreements, and actively monitoring supply chain risks and geopolitical factors.

5. What is the typical shelf-life of sevelamer carbonate API? The typical shelf-life of sevelamer carbonate API, when stored under recommended conditions, is generally two to three years. Specific shelf-life and retest periods are determined by stability studies conducted by the manufacturer and detailed in regulatory submissions.

Citations

[1] Gout, P. (2011). Sevelamer carbonate. Nature Reviews Drug Discovery, 10(12), 885–885. doi:10.1038/nrd3591